Correlative Indexes in Prediction of Survival in Refractory Metastatic Lung Adenocarcinoma. The Role of Liquid Biopsy to Assess Survival

In refractory metastatic lung adenocarcinoma, liquid biopsy can provide valuable insights into survival, particularly in identifying resistance mechanisms and monitoring treatment response. For example, circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) can reveal EGFR mutation status. Heterogenous tumors are defined based on their genomic signature consisting of a variety of biomarkers. Aa major problem, remains as we are unable to translate a “target response” to a “clinical response”. This problem would be even further complicated by implementing targeted therapies that can cause resistance by inducing mutations in the DNA as well as enhancing the process called “selective advantage” of the resistant cells. Since the resistance of the tumor correlates with the patient’s survival, using liquid biopsy can detect early resistance and therefore predict prognosis.

Authors

Publication Details

Journal
Journal of Clinical Case Studies Reviews & Reports
Published
2025-06-19
DOI
https://doi.org/10.47363/jccsr/2025(7)354
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Correlative Indexes in Prediction of Survival in Refractory Metastatic Lung Adenocarcinoma. The Role of Liquid Biopsy to Assess Survival

M. A. Nezami
Journal of Clinical Case Studies Reviews & Reports
Cancer Genomics and Diagnostics
article

Correlative Indexes in Prediction of Survival in Refractory Metastatic Lung Adenocarcinoma. The Role of Liquid Biopsy to Assess Survival

M. A. Nezami
article en

Abstract

In refractory metastatic lung adenocarcinoma, liquid biopsy can provide valuable insights into survival, particularly in identifying resistance mechanisms and monitoring treatment response. For example, circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) can reveal EGFR mutation status. Heterogenous tumors are defined based on their genomic signature consisting of a variety of biomarkers. Aa major problem, remains as we are unable to translate a “target response” to a “clinical response”. This problem would be even further complicated by implementing targeted therapies that can cause resistance by inducing mutations in the DNA as well as enhancing the process called “selective advantage” of the resistant cells. Since the resistance of the tumor correlates with the patient’s survival, using liquid biopsy can detect early resistance and therefore predict prognosis.

Journal of Clinical Case Studies Reviews & Reports
Good health and well-being
Openalex Percentile: Top 80%
Cancer Genomics and Diagnostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.